Australia markets closed

Eupraxia Pharmaceuticals Inc. (EPRX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.6100-0.0300 (-1.14%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 94.60M
Enterprise value 68.25M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.76
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.85

Trading information

Stock price history

Beta (5Y monthly) 1.17
52-week change 3-11.53%
S&P500 52-week change 326.24%
52-week high 33.5000
52-week low 32.4800
50-day moving average 32.7929
200-day moving average 32.8003

Share statistics

Avg vol (3-month) 328.15k
Avg vol (10-day) 313.6k
Shares outstanding 535.62M
Implied shares outstanding 636.3M
Float 829.91M
% held by insiders 16.93%
% held by institutions 111.89%
Shares short (15 May 2024) 420.44k
Short ratio (15 May 2024) 40.91
Short % of float (15 May 2024) 4N/A
Short % of shares outstanding (15 May 2024) 40.04%
Shares short (prior month 15 Apr 2024) 44.42k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-75.51%
Return on equity (ttm)-267.25%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -30.89M
Net income avi to common (ttm)-30.37M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)35.91M
Total cash per share (mrq)1.01
Total debt (mrq)9.56M
Total debt/equity (mrq)52.78%
Current ratio (mrq)1.95
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-22.24M
Levered free cash flow (ttm)-11.28M